⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMNM News
Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
IMNM
Form 8-K
sec.gov
IMNM
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
businesswire.com
IMNM
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
globenewswire.com
PRLD
MRNA
IMNM
AUTL
ONCY
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
Immunome Announces Pricing of Public Offering of Common Stock
businesswire.com
IMNM
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
globenewswire.com
ONCY
IMNM
PRLD
CNTX
RLAY
Immunome Announces Proposed Public Offering of Common Stock
businesswire.com
IMNM
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
businesswire.com
IMNM
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
businesswire.com
IMNM